Fate Therapeutics Statistics Share Statistics Fate Therapeutics has 115.33M
shares outstanding. The number of shares has increased by 0.66%
in one year.
Shares Outstanding 115.33M Shares Change (YoY) 0.66% Shares Change (QoQ) 0.03% Owned by Institutions (%) 81.48% Shares Floating 109.47M Failed to Deliver (FTD) Shares 2,400 FTD / Avg. Volume 0.14%
Short Selling Information The latest short interest is 9.4M, so 8.15% of the outstanding
shares have been sold short.
Short Interest 9.4M Short % of Shares Out 8.15% Short % of Float 9.3% Short Ratio (days to cover) 6.09
Valuation Ratios The PE ratio is -1.01 and the forward
PE ratio is -0.88.
Fate Therapeutics's PEG ratio is
0.
PE Ratio -1.01 Forward PE -0.88 PS Ratio 13.76 Forward PS 20.7 PB Ratio 0.59 P/FCF Ratio -1.52 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Fate Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.58,
with a Debt / Equity ratio of 0.27.
Current Ratio 7.58 Quick Ratio 7.58 Debt / Equity 0.27 Debt / EBITDA -0.48 Debt / FCF -0.69 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $75.31K Profits Per Employee $-1.03M Employee Count 181 Asset Turnover 0.03 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -70.21% in the
last 52 weeks. The beta is 2.22, so Fate Therapeutics's
price volatility has been higher than the market average.
Beta 2.22 52-Week Price Change -70.21% 50-Day Moving Average 1.11 200-Day Moving Average 1.32 Relative Strength Index (RSI) 43.22 Average Volume (20 Days) 1,679,467
Income Statement In the last 12 months, Fate Therapeutics had revenue of 13.63M
and earned -186.26M
in profits. Earnings per share was -1.64.
Revenue 13.63M Gross Profit 13.63M Operating Income -210.28M Net Income -186.26M EBITDA -176.58M EBIT -195.54M Earnings Per Share (EPS) -1.64
Full Income Statement Balance Sheet The company has 36.06M in cash and 85.27M in
debt, giving a net cash position of -49.21M.
Cash & Cash Equivalents 36.06M Total Debt 85.27M Net Cash -49.21M Retained Earnings -1.4B Total Assets 371.63M Working Capital 201.72M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -122.87M
and capital expenditures -730K, giving a free cash flow of -123.6M.
Operating Cash Flow -122.87M Capital Expenditures -730K Free Cash Flow -123.6M FCF Per Share -1.09
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -1542.63% and -1366.46%.
Gross Margin 100% Operating Margin -1542.63% Pretax Margin -1366.46% Profit Margin -1366.46% EBITDA Margin -1295.41% EBIT Margin -1542.63% FCF Margin -906.79%
